Main Concerns of G-Med Physicians on the Topic of CKD

Topics/keywords: ‘chronic kidney disease’, ‘ckd’

Data types: posts, comments, likes, polls

Geographical segment: global physicians, physicians by region

Analyzed data points on G-Med: 17,937

Specialties: Nephrology, Internal Medicine, Family Medicine, Cardiology, Diabetes and Endocrinology

Countries analyzed: 66

Reach: 20,180

Introduction

This report presents an evidence-based analysis of physician discussions surrounding Chronic Kidney Disease (CKD) from the G-Med platform. It is based on unique posts and comments from global healthcare professionals. Data was collected via keyword-based filtering and analyzed using thematic mapping, sentiment assessment, and content clustering. All relevant post and comment text fields were standardized and translated for consistency. This report highlights the most pressing clinical concerns and practice trends, including regional variations where applicable.

Main Concerns of G-Med Physicians on the Topic of Chronic Kidney Disease (CKD)

Hypertension Control in CKD (26% of physician discussions)

75% of discussions were positive regarding current treatment options, focusing on effective blood pressure management using ACE inhibitors and ARBs.
25% expressed concern over treatment resistance or side effects, especially in late-stage CKD.

Diabetes in CKD (21%)

79% supported tight glycemic control and the benefits of SGLT2 inhibitors.
21% voiced concerns over risk of hypoglycemia and drug safety in advanced CKD.

CKD Progression Monitoring (13%)

56% of physicians viewed eGFR and creatinine tracking as essential and improving.
44% expressed skepticism about over-reliance on these markers in elderly or comorbid patients.

CKD and Cardiovascular Risk (10%)

84% showed proactive approaches toward using statins and risk stratification tools. Discussing cardiorenal syndrome and the interplay between heart failure and CKD, particularly in relation to volume overload, diuretic resistance, and worsening renal function.
16% raised concern over polypharmacy and limited impact on long-term outcomes.

Hyperkalemia Management (8%)

72% supported newer binders like patiromer and Lokelma for safer potassium control.
28% questioned efficacy or long-term tolerability.

Anemia Management (6%)

63% emphasized benefits of iron supplementation and erythropoiesis-stimulating agents (ESAs).
37% expressed hesitation due to thrombotic risks or ESA resistance.

Dialysis Modality Selection (6%)

78% favored shared decision-making and early planning between HD and PD.
22% cited infrastructure or patient compliance barriers.

Mineral and Bone Disorder (5%)

68% endorsed use of phosphate binders, vitamin D analogs, and cinacalcet.
32% flagged persistent control challenges and underdiagnosis.

Interested in a similar report for your field? Contact us here

Key Points on Diagnosis, Treatment, and Follow-Up

Exacerbating Factors (14% of physician discussions)

NSAID Use and Nephrotoxins: 55% of discussions cited NSAID use or other nephrotoxins as common triggers for acute worsening of kidney function on a background of CKD.
Infections and Acute Illness: 36% of physicians linked infection-related complications (e.g., sepsis, UTIs, dehydration) to episodes of acute kidney injury (AKI) in CKD patients.

Diagnosis (25%)

Early Detection and Biomarkers: majority of discussions mentioned creatinine, eGFR, and urine protein levels; 77% expressed confidence in these tools, while 20% noted missed cases in asymptomatic patients.
Risk Stratification: Some discussed novel scoring systems and CKD staging based on eGFR and albuminuria.
Underdiagnosis in Primary Care: Limited awareness among non-specialists was flagged as a gap.

Treatment (39%)

Blood Pressure & Glycemic Control: 83% supported aggressive control using ACE inhibitors, ARBs, and SGLT2 inhibitors.
Pharmacologic Caution: 14% raised concerns over polypharmacy, NSAID use, and contraindicated drugs in CKD.
Renal Replacement Therapy and Dialysis: While most discussions on CKD did not address dialysis directly, those that did focused on complications such as edema, immunosuppression, and encephalopathy.

Follow-Up (17%)

Adherence & Monitoring: 86% promoted structured biochemical follow-up for patients recently discharged from an in-patient setting, as well as for stable patients
Long-Term Planning: Conversations included dietary education and comorbidity management.
Care Gaps: 14% highlighted missed visits or fragmented communication between specialists and primary care.

Geographical Analysis of Physician Discussions on CKD

Of the 66 countries analyzed, the following topics were discussed in prominent countries:

United States

Strong engagement in hypertension and diabetes control, with emphasis on ACE inhibitors and SGLT2 inhibitors.
High positive sentiment around cardioprotective strategies.

United Kingdom

Frequent discussions on monitoring strategies and early referral to nephrology.
Interest in optimizing follow-up plans for late-stage CKD patients.

Spain & Italy

Dialysis modality and anemia management were dominant themes.
Physicians debated timing of ESA use and iron repletion strategies.

Germany & France

Structured follow-up and CKD-mineral bone disorder (CKD-MBD) were emphasized.
Higher confidence in phosphate binder protocols and secondary hyperparathyroidism management.

India

Concerns over delayed diagnosis and lack of access to dialysis centers.
Highlighted affordability issues with newer therapies like SGLT2 inhibitors and potassium binders.

Cross-Country Differences in CKD Discussions

This section highlights dimensions where physician discussions diverged across countries.

Structured vs. Fragmented Follow-Up Models

This theme contrasts countries where CKD follow-up is standardized versus those where physicians reported inconsistent or uncoordinated care:

Structured Follow-Up: Most strongly emphasized in Germany, France, the United States, and the United Kingdom, where physicians discussed routine monitoring protocols, consistent lab testing, and stage-based management plans.
Fragmented Follow-Up: Described more frequently in Brazil and Mexico, where physicians cited challenges with missed visits, limited coordination between providers, and inadequate patient tracking.

Confidence vs. Concern in New Therapeutics

This theme reflects physician sentiment toward newer CKD medications and treatment strategies:

Confidence in New Therapeutics: Discussions in the United States, Germany, Brazil, and Canada showed strong support for agents like SGLT2 inhibitors and potassium binders, often citing improved outcomes and reduced progression risk.
Concerns and Access Barriers: In Spain and Italy, many discussions raised concerns about affordability, side effects, or limited access to newer treatments—particularly in public healthcare settings.